Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled …

RL Coleman, AM Oza, D Lorusso, C Aghajanian… - The Lancet, 2017 - thelancet.com
Background Rucaparib, a poly (ADP-ribose) polymerase inhibitor, has anticancer activity in
recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome …

Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway

JI Weberpals, KV Clark-Knowles… - Journal of Clinical …, 2008 - ascopubs.org
Among the most promising pathways for molecular targets in sporadic epithelial ovarian
cancer (SEOC) are those involving the BRCA1 protein. Because somatic mutations in …

Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial

S Lheureux, MC Cristea, JP Bruce, S Garg… - The Lancet, 2021 - thelancet.com
Summary Background The Wee1 (WEE1hu) inhibitor adavosertib and gemcitabine have
shown preclinical synergy and promising activity in early phase clinical trials. We aimed to …

Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised …

JA Ledermann, AM Oza, D Lorusso… - The Lancet …, 2020 - thelancet.com
Background In ARIEL3, rucaparib maintenance treatment significantly improved progression-
free survival versus placebo. Here, we report prespecified, investigator-assessed …

Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer

JI Weberpals, M Koti, JA Squire - Cancer genetics, 2011 - Elsevier
Genomic information is being used to develop robust prognostic and predictive biomarkers
that will provide companion diagnostics for emerging molecular targeted therapies. The …

A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian …

AM Oza, M Estevez-Diz, EM Grischke, M Hall… - Clinical Cancer …, 2020 - AACR
Purpose: Preclinical studies show that adavosertib, a WEE1 kinase inhibitor, sensitizes
TP53-mutant cells to chemotherapy. We hypothesized that adavosertib, plus chemotherapy …

A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A …

I Diaz-Padilla, MK Wilson, BA Clarke, HW Hirte… - Gynecologic …, 2015 - Elsevier
Purpose A phase II study was performed to evaluate the efficacy and safety of single-agent
RO4929097 (a gamma-secretase inhibitor) in patients with recurrent platinum-resistant …

[HTML][HTML] Patient-centered outcomes in ARIEL3, a phase III, randomized, placebo-controlled trial of rucaparib maintenance treatment in patients with recurrent ovarian …

AM Oza, D Lorusso, C Aghajanian… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of
Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma - PMC Back …

Vulvar squamous cell carcinoma (VSCC) as two diseases: HPV status identifies distinct mutational profiles including oncogenic fibroblast growth factor receptor 3

JI Weberpals, B Lo, MM Duciaume, JN Spaans… - Clinical Cancer …, 2017 - AACR
Purpose: Patients with advanced or recurrent invasive vulvar squamous cell carcinoma
(VSCC) have limited treatment options and a grave prognosis. Understanding the genomic …

[HTML][HTML] Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response

SE Willis, C Winkler, MP Roudier, T Baird… - British Journal of …, 2021 - nature.com
Background The absence of the putative DNA/RNA helicase Schlafen11 (SLFN11) is
thought to cause resistance to DNA-damaging agents (DDAs) and PARP inhibitors. Methods …